Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2024-10, Vol.86 (4), p.e88-e89
Hauptverfasser:	Ding, Li, Yang, Bin, Yao, Xudong
Format:	Artikel
Sprache:	eng
Schlagworte:	Androstenes - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials, Phase III as Topic Double-Blind Method Humans Male Phthalazines - therapeutic use Piperazines - therapeutic use Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Prostatic Neoplasms, Castration-Resistant - pathology Randomized Controlled Trials as Topic Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!